Abstract
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Frederick Wolfe, Nancy Flowers, Thomas A Burke, Lester M Arguelles and Dan Pettitt
The Journal of Rheumatology May 2002, 29 (5) 1015-1022;
Frederick Wolfe
Nancy Flowers
Thomas A Burke
Lester M Arguelles
In this issue
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Frederick Wolfe, Nancy Flowers, Thomas A Burke, Lester M Arguelles, Dan Pettitt
The Journal of Rheumatology May 2002, 29 (5) 1015-1022;
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Frederick Wolfe, Nancy Flowers, Thomas A Burke, Lester M Arguelles, Dan Pettitt
The Journal of Rheumatology May 2002, 29 (5) 1015-1022;